VBI Vaccines Inc. (NASDAQ:VBIV) announced positive top-line data from its Phase III PROTECT trial comparing its Sci-B-Vac trivalent hepatitis B vaccine to GlaxoSmithKline’s Engerix-B vaccine. The trial found that Sci-B-Vac was non-inferior to Engerix-B, two of its primary endpoints. Those endpoints were non-inferiority in all adults 18 years of age and older and superiority in adults 45 years of age or older. However, the trial did not meet the secondary endpoint, non-inferiority in two doses of Sci-B-Vac at day 168 compared with three doses of Engerix-B at day 196.
VBI Vaccines Inc. (NASDAQ:VBIV), a Healthcare sector firm, traded 7.59 Million shares in last trading session with closing price of $1.29 per share. Stock value has moved between $0.58 – 3.23 in last one year. Analyst’s mean target price for VBI Vaccines Inc. (NASDAQ:VBIV) is $8.25 while analysts mean recommendation is 1.50. VBIV EPS growth this year is 0.00%.
On last trading day, India Globalization Capital, Inc. (NYSE:IGC) shares closed at $2.05 per share. IGC market capitalization is 70.56 with beta of 6.35. Its weekly performance is 70.83% while year to date (YTD) performance is 632.14%.
In last session Melinta Therapeutics, Inc. (NASDAQ:MLNT) traded 5.15 Million shares and was closed at $5.89. Analyst’s mean target price for MLNT is $48.75 while analysts mean recommendation is 2.50. Company is -84.29% away from its 52 week high and is moving 263.58% ahead of its 52 week low. MLNT Gross Margin is 57.40% and its return on assets is -32.30%. Melinta Therapeutics, Inc. (NASDAQ:MLNT) quarterly performance is 55.82% while its price to sale ratio is 0.76.
Caesars Entertainment Corporation (NASDAQ:CZR), a Services sector firm, traded 219.19 Million shares on last trading day with closing price of $11.44 per share. Company gross margin stands at 52.70% whereas its return on investment (ROI) is 3.50%. Stock value has moved between $5.84 – 11.92 in last one year. Analyst’s mean target price for Caesars Entertainment Corporation (NASDAQ:CZR) is $11.07 while analysts mean recommendation is 2.20. CZR EPS growth this year is 104.60%.
